Does Supplementation with Omega-3 PUFAs Add to the Prevention of Cardiovascular Disease?
- 846 Downloads
Purpose of Review
Omega-3 fatty acids are increasingly used for the protection of cardiovascular disease. The main but not the sole mechanism of action is the reduction of triglyceride levels. In this review, we summarize the effect of omega-3 supplements on all-cause and cardiovascular mortality, myocardial infarction, and stroke from the relevant randomized controlled trials.
Twenty-one randomized controlled trials assessed omega-3 supplementation on mortality and cardiovascular-related outcomes. From these studies, as well as from the relevant meta-analyses, we found that omega-3 supplements do not exert a consistent benefit for cardiovascular protection.
There is uncertainty of a clear profit from omega-3 supplementation in cardiovascular disease.
KeywordsOmega 3 Polyunsaturated fatty acids Fish oil Cardiovascular Myocardial infarction Death
Compliance with Ethical Standards
Conflict of Interest
Both authors comply with ethical standards and are in line with best practices and codes of conduct of relevant professional bodies and/or national and international regulatory bodies. This study was not funded. The authors have received no payment in preparation of this manuscript. Evangelos C. Rizos and Moses S. Elisaf have given talks, attended conferences, and participated in trials and advisory boards sponsored by various pharmaceutical companies (Novartis, Sanofi, NovoNordisk, Pfizer, AstraZeneca/BMS, Eli Lilly, MSD/Vianex, Boehringer Ing, Amgen, GSK, Plus Pharmaceuticals, WinMedica, Elpen etc.).
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 1.• Alexander DD, Miller PE, Van Elswyk ME, Kuratko CN, Bylsma LC. A meta-analysis of randomized controlled trials and prospective cohort studies of eicosapentaenoic and docosahexaenoic long-chain omega-3 fatty acids and coronary heart disease risk. Mayo Clin Proc. 2017;92(1):15–29. The latest meta-analysis on the field Google Scholar
- 3.Trikalinos T.A., Lee J., Moorthy D., Yu W.W., Lau J., Lichtenstein A.H., Chung M., 2012. Effects of eicosapentanoic acid and docosahexanoic acid on mortality across diverse settings: systematic review and meta-analysis of randomized trials and prospective cohorts. Rockville (MD): Agency for Healthcare Research and Quality (US).Google Scholar
- 4.Kwak SM, Myung SK, Lee YJ, Seo HG, for the Korean Meta-analysis Study Group. Efficacy of omega-3 fatty acid supplements (Eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: a meta-analysis of randomized, double-blind, placebo-controlled trials. Arch Intern Med. 2012;172:686–94.CrossRefPubMedGoogle Scholar
- 6.Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney MT, Corrà U, Cosyns B, Deaton C, Graham I, Hall MS, Hobbs FD, Løchen ML, Löllgen H, Marques-Vidal P, Perk J, Prescott E, Redon J, Richter DJ, Sattar N, Smulders Y, Tiberi M, van der Worp HB, van Dis I, Verschuren WM, Authors/Task Force Members. 2016 European guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315–81.CrossRefPubMedGoogle Scholar
- 7.Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WM, Vlachopoulos C, Wood DA, Zamorano JL, Authors/Task Force Members.; Additional Contributor. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37(39):2999–3058.CrossRefPubMedGoogle Scholar
- 8.Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S1–S45.CrossRefPubMedGoogle Scholar
- 9.Food and Drug Administration. Lovaza: GlaxoSmithKline. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021654s034lbl.pdf. Accessed December 20, 2016.
- 10.Electronic Medicines Compendium. Omacor: Abbott Healthcare Products Limited. http://www.medicines.org.uk/emc/medicine/10312 /indications. Accessed December 20, 2016.
- 20.Mozaffarian D, Marchioli R, Macchia A, Silletta MG, Ferrazzi P, Gardner TJ, Latini R, Libby P, Lombardi F, O’Gara PT, Page RL, Tavazzi L, Tognoni G, OPERA Investigators. Fish oil and postoperative atrial fibrillation: the omega-3 fatty acids for prevention of post-operative atrial fibrillation (OPERA) randomized trial. JAMA. 2012;308:2001–11.CrossRefPubMedPubMedCentralGoogle Scholar
- 26.Singh RB, Niaz MA, Sharma JP, Kumar R, Rastogi V, Moshiri M. Randomized, double-blind, placebo controlled trial of fish oil and mustard oil in patients with suspected acute myocardial infarction: the Indian experiment of infarct survival. Cardiovasc Drugs Ther. 1997;11(3):485–91.CrossRefPubMedGoogle Scholar
- 29.Marchioli R, Barzi F, Bomba E, et al; GISSI-prevenzione investigators. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI)-Prevenzione. Circulation 2002; 105(16):1897–1903.Google Scholar
- 31.Leaf A, Albert CM, Josephson M, et al; Fatty acid antiarrhythmia trial investigators. Prevention of fatal arrhythmias in high-risk subjects by fish oil n-3 fatty acid intake. Circulation 2005; 112(18):2762–2768.Google Scholar
- 33.Brouwer IA, Zock PL, Camm AJ, SOFA Study Group, et al. Effect of fish oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defibrillators: the study on omega-3 fatty acids and ventricular arrhythmia (SOFA) randomized trial. JAMA. 2006;295(22):2613–9.CrossRefPubMedGoogle Scholar
- 34.Svensson M, Schmidt EB, Jørgensen KA, Christensen JH, OPACH Study Group. N-3 fatty acids as secondary prevention against cardiovascular events in patients who undergo chronic hemodialysis: a randomized, placebo-controlled intervention trial. Clin J Am Soc Nephrol. 2006;1(4):780–6.CrossRefPubMedGoogle Scholar
- 35.Yokoyama M, Origasa H, Matsuzaki M, et al; Japan EPA lipid intervention study (JELIS) investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomized open-label, blinded endpoint analysis. Lancet 2007; 369(9567):1090–1098.Google Scholar
- 36.Tavazzi L, Maggioni AP, Marchioli R, et al; GISSI HF Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo controlled trial. Lancet 2008; 372(9645):1223–1230.Google Scholar
- 39.Kromhout D, Giltay EJ, Geleijnse JM; Alpha Omega Trial Group. N-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med 2010; 363(21):2015–2026.Google Scholar
- 42.Bosch J, Gerstein HC, Dagenais GR, et al; ORIGIN trial Investigators. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med 2012; 367(4):309–318.Google Scholar
- 44.Macchia A, Grancelli H, Varini S, et al; GESICA Investigators. Omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: results of the FORWARD (randomized trial to assess efficacy of PUFA for the maintenance of sinus rhythm in persistent atrial fibrillation) trial. J Am Coll Cardiol 2013; 61(4):463–468.Google Scholar
- 45.Bonds DE, Harrington M, Worrall BB, et al. Writing group for the AREDS2 Research Group. Effect of long-chain ω-3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the age-related eye disease study 2 (AREDS2) randomized clinical trial. JAMA Intern Med 2014; 174(5):763–771.Google Scholar
- 47.• Kantor ED, Rehm CD, Du M, White E, Giovannucci EL. Trends in dietary supplement use among US adults from 1999-2012. JAMA. 2016;316(14):1464–74. Real-world data show increasingly used omega-3 formulations Google Scholar